Agios Pharmaceuticals to Seek Accelerated FDA Approval for Mitapivat in Sickle Cell Disease

Key Facts

Agios Pharmaceuticals (Nasdaq: AGIO) announced its intention to pursue accelerated approval from the U.S. Food and Drug Administration (FDA) for its drug mitapivat. The treatment is designed for patients suffering from sickle cell disease, a chronic and debilitating blood disorder. This strategic decision follows a successful pre-sNDA meeting with the regulator, which confirmed the viability of the accelerated approval pathway. The company is currently working with the FDA to align on the design of a required confirmatory trial to support the submission. Agios plans to formally submit the supplemental New Drug Application (sNDA) in the coming months. Investors view this development as a significant step toward shortening the timeline for commercializing a key pipeline asset.